💊 Médicaments A-Z 🧬 Cibles 🛠 Outils 📚 Guides
Tous les médicaments Classes de médicaments Aires thérapeutiques Effets Indésirables
Guides Glossaire Chronologie
Comparaisons Parcours des médicaments Familles de médicaments
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Vutrisiran Sodium

CHEMBL5095303 Phase 4 Approuvé Oligonucleotide
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
— g/mol
LogP
—
Phase
4

Vutrisiran sodium is the sodium salt form of vutrisiran, a GalNAc-siRNA therapeutic that silences transthyretin gene expression in hepatocytes to reduce TTR protein production and amyloid formation in hereditary TTR amyloidosis. The sodium salt form is used in the injectable formulation for subcutaneous administration. Quarterly subcutaneous dosing of vutrisiran sodium provides sustained TTR suppression for polyneuropathy management in hATTR amyloidosis.

Mécanisme d'action

Delivers synthetic messenger RNA encoding a specific protein to host cells, where it is translated by ribosomes to produce the therapeutic protein without integrating into the host genome.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mécanisme

Delivers synthetic messenger RNA encoding a specific protein to host cells, where it is translated by ribosomes to produce the therapeutic protein without integrating into the host genome.

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

Vutrisiran sodium is the sodium salt form of vutrisiran, a GalNAc-siRNA therapeutic that silences transthyretin gene expression in hepatocytes to reduce TTR protein production and amyloid formation in hereditary TTR amyloidosis. The sodium salt form is used in the injectable formulation for subcutaneous administration. Quarterly subcutaneous dosing of vutrisiran sodium provides sustained TTR suppression for polyneuropathy management in hATTR amyloidosis.

Delivers synthetic messenger RNA encoding a specific protein to host cells, where it is translated by ribosomes to produce the therapeutic protein without integrating into the host genome.

Yes, Vutrisiran Sodium is an approved drug. It has reached clinical phase 4. It is classified as a Oligonucleotide.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL5095303. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.